Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
AORT: Section 144 notice reporting restricted stock vesting and recent insider sales.
The filing lists 6,316 common shares associated with a restricted stock vesting event on 02/27/2026. It also discloses three sales by Lance Berry: 4,981 shares (proceeds $187,223.34) on 02/23/2026, 4,885 shares (proceeds $160,082.66) on 02/24/2026, and 5,178 shares (proceeds $196,892.93) on 03/02/2026.
John E. Davis reported insider share transactions under Form 144 relating to AORT common stock. The filing lists proposed restricted-stock vesting of 4,573 shares on 02/27/2026 and discloses sales executed in the prior three months: 3,773 shares on 02/23/2026 ($141,817.64), 2,075 shares on 02/24/2026 ($74,062.77), and 2,784 shares on 03/02/2026 ($105,861.32).
AORT reported proposed insider sales of Common Stock under Form 144 by Jean F. Holloway. The filing lists sales on 02/23/2026 of 3,079 shares for $115,731.92, on 02/24/2026 of 1,668 shares for $59,535.76, and on 03/02/2026 of 2,183 shares for $83,008.36. The broker listed is Fidelity Brokerage Services LLC with an execution reference date of 03/03/2026.
AORT reported proposed sales of common stock via Form 144 by an affiliated holder. The notice lists proposed dispositions of 2,423, 1,259, and 1,513 shares on 02/23/2026, 02/24/2026, and 03/02/2026, respectively, with corresponding proceeds shown. The filing also shows 2,149 restricted shares vested on 02/27/2026.
AORT filed a Form 144 notifying the proposed sale of 17,887 shares of common stock dated 02/27/2026 associated with restricted stock vesting.
The filing also reports prior sales by James Mackin: 30,921 shares on 12/03/2025, 20,962 shares on 02/23/2026, 13,936 shares on 02/24/2026, and 14,911 shares on 03/02/2026, with each sale accompanied by the reported sale proceeds in the excerpt.
Amy D. Horton filed a Form 144 reporting an intended sale of 901 shares of Common stock. The filing lists the securities to be sold as 901 shares tied to 02/27/2026 described as Restricted Stock Vesting under compensation.
The filing also discloses prior market sales of Common stock during the past three months: 4,572 shares on 12/08/2025 for $203,081.38, 1,731 shares on 02/23/2026 for $65,063.96, 830 shares on 02/24/2026 for $29,625.11, and 641 shares on 03/02/2026 for $24,373.96.
Artivion, Inc. executive reports tax-related share sale. VP and Chief Accounting Officer Amy Horton disposed of 641 shares of common stock in an open-market transaction at about $38.02 per share. According to the footnote, the shares were sold automatically to cover tax withholding upon restricted stock unit vesting and were not a discretionary trade. After this transaction, she directly holds 132,514 shares.
Artivion, Inc. senior vice president Stanton Marshall S. reported an automatic sale of 1,513 shares of common stock at an average price of $38.0249 per share. According to the filing, the shares were sold upon vesting of restricted stock units solely to cover tax withholding obligations and were not a discretionary trade. After this transaction, he directly holds 40,408 shares of Artivion common stock.
Artivion, Inc. President and CEO James P. Mackin reported an open-market sale of 14,911 shares of common stock at an average price of $38.0249 per share. According to the footnote, the shares were sold solely to cover tax withholding obligations upon the vesting of restricted stock units and did not represent a discretionary transaction. After this sale, Mackin beneficially owned 848,214 shares of Artivion common stock directly.
Artivion, Inc. senior vice president and general counsel Jean F. Holloway reported an automatic sale of company stock related to tax withholding. On this Form 4, she disposed of 2,183 shares of common stock at a weighted average price of $38.0249 per share in an open-market transaction. A footnote explains that the shares were sold upon the vesting of restricted stock units solely to cover tax withholding obligations through a “sell to cover” arrangement and did not represent a discretionary trade. After this transaction, Holloway directly owned 170,105 shares of Artivion common stock.